Anthony Rullo: chemically modulating proximity

Confinement Catalysis Enables Macrocyclization at Up to 0.6 M: Selective Formation of Mono- and Dimeric Glycosidic Macrocycles | Journal of the American Chemical Society pubs.acs.org/doi/10.1021/ja…

Beyond traditional strain-promoted azide–alkyne cycloadditions by achieving orthogonality and rapid kinetics with fluoroalkyl azides Nature Communications 2026 nature.com/articles/s4200…

Discovery of Ultrapotent Heterodimeric Peptide Ligands Using Library-vs-Library RaPID Selections | Journal of the American Chemical Society pubs.acs.org/doi/10.1021/ja…

AI‐Based Prediction of PROTAC‐ and Molecular Glue‐Mediated Ternary Complexes: A Comparative Evaluation of AlphaFold 3 and Boltz‐2 - Riepenhausen - 2026 - Archiv der Pharmazie - Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/ar…

A logic-gated trispecific engager enhances macrophage killing of cancer cells in solid tumors go.nature.com/4uC0qiM

@vishal_iiserb @Novartis proximity effects ? ;)

@Novartis La Jolla site that contributes significantly to healthcare. Scripps and UCSD in the proximity creates an excellent basic-translational research ecosystem.

@SebVidalChem @dr_kuato

@LabRullo @dr_kuato

Editor's desk response when authors come from... South America Europe/USA/China

@SebVidalChem @dr_kuato Canada isn't having a terribly easy time either....journal depending .....

@dr_kuato I am currently having more trouble than ever to publish some papers, from France....

Nature holds the keys to PPIs—why don't we use them? Some thoughts on stabilizing hotspots without sequence changes, using the emerging non-symmetric stapling. This could unlock the therapeutic potential of native peptides. Now out as @ChemRxiv preprint. chemrxiv.org/doi/full/10.26…

Farewell to a giant in chemical immunology and induced proximity

@chopralab I'm so sorry to hear this. His contributions to synthetic immunology were an inspiration

Today I lost a dear friend, mentor, and colleague. Dr. Philip Low was a brilliant scientist whose discoveries transformed human health. I’m deeply saddened by Phil’s passing and grateful for his friendship and mentorship. His legacy will endure. purdue.edu/newsroom/2026/…

@jaybradner haha, or maybe some heterobifunctional sugars ?

Happy Birthday, Ty! Good boy. Have some cheese.

@MarkLautens @glycoworld i'm so sorry to hear this

A very sad day for the Department of Chemistry as we mourn the death of Professor Dwight Seferos. Gone way too young.

Tetrazine-Mediated Bioorthogonally Activated Therapeutic (TBAT) Platforms | Journal of the American Chemical Society pubs.acs.org/doi/10.1021/ja…

A @nchembio study led by Assoc. Prof. @Michael_A_Erb describes a strategy to deliberately discover “molecular glue” degraders by converting existing protein binders into compounds that recruit the cell’s disposal machinery, selectively degrading ENL and BRD4. More: ow.ly/Fqrr50YoenT

Awesome new @biorxivpreprint from @Keribackus and Amit Choudhary @harvardmed. A modular platform for #proximity #pharmacology. Converting known inhibitors into PTM writer/erasers, using endogenous proteins, tunable Lys/Cys-targeting chemistry. Great read! biorxiv.org/content/10.648…

'Lock-and-key' chemistry keeps cancer drugs inactive until they reach tumor sites phys.org/news/2026-02-k…

Development of Nanomolar Affinity Miniprotein Inhibitors Targeting α-Synuclein Aggregation as Promising Therapeutic Agents for Parkinson’s Disease chinesechemsoc.org/doi/10.31635/c… #chemistry #openaccess #science #chemtwitter

@MedChem314 @scrippsresearch @BogerLab This is outstanding ! Congratulations

A vital antibiotic is failing. One chemist’s fix could work for centuries. These maxamycins proved to be potent, durable,& efficacious antimicrobial agents that display equipotent activity against vancomycin-sensitive & vancomycin-resistant Gram+ org. @scrippsresearch @BogerLab

MAXAMYCINS: Durable Antibiotics Derived by Rational Redesign of Vancomycin | Accounts of Chemical Research Boger and Wu Acc. Chem. Res. 2020, 53, 11, 2587–2599 share.google/lPntLzSnKxX0AR…

Lysine Targeting: A Next-Generation Option for Covalent Inhibitors | drughunters.com/472JlnF Since the FDA approval of afatinib and ibrutinib in 2013, cysteine-targeted covalent inhibitors have become an important strategy in drug discovery. However, cysteines are scarce, mutation-prone thiols, so medicinal chemists are now turning to catalytic lysines because they are more abundant, functionally essential, and often harder for tumors to “escape” by mutation. A growing toolkit of lysine-reactive warheads is enabling selective covalent engagement across kinases and beyond. From chemoproteomic probes that can map ligandable lysines at scale, to lysine targeting small molecule inhibitors moving toward clinical development, this review highlights the emerging capabilities afforded by lysine-targeting. Read it on Drug Hunter: drughunters.com/472JlnF